Assenagon Asset Management S.A. Decreases Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Assenagon Asset Management S.A. reduced its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 28.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 475,409 shares of the life sciences company’s stock after selling 190,823 shares during the quarter. Assenagon Asset Management S.A. owned about 0.61% of Integra LifeSciences worth $20,704,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Itau Unibanco Holding S.A. raised its position in shares of Integra LifeSciences by 469.5% in the 2nd quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock valued at $31,000 after purchasing an additional 615 shares during the last quarter. Gladius Capital Management LP purchased a new position in shares of Integra LifeSciences in the 3rd quarter valued at approximately $47,000. Covestor Ltd raised its position in shares of Integra LifeSciences by 82.5% in the 3rd quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock valued at $78,000 after purchasing an additional 921 shares during the last quarter. Coppell Advisory Solutions LLC purchased a new position in shares of Integra LifeSciences in the 2nd quarter valued at approximately $84,000. Finally, Captrust Financial Advisors raised its position in Integra LifeSciences by 95.0% during the 1st quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock worth $129,000 after buying an additional 976 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Price Performance

Integra LifeSciences stock opened at $34.83 on Thursday. Integra LifeSciences Holdings Co. has a 52-week low of $33.24 and a 52-week high of $59.33. The firm has a market capitalization of $2.72 billion, a price-to-earnings ratio of 41.96, a PEG ratio of 1.01 and a beta of 1.13. The company has a fifty day simple moving average of $39.63 and a 200-day simple moving average of $39.73. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The business had revenue of $397.00 million for the quarter, compared to analysts’ expectations of $399.30 million. During the same period in the previous year, the company earned $0.94 EPS. Integra LifeSciences’s quarterly revenue was down .3% compared to the same quarter last year. On average, equities analysts anticipate that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on IART. Truist Financial reduced their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research report on Friday, March 1st. JMP Securities reduced their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research report on Thursday, February 29th. Wells Fargo & Company raised shares of Integra LifeSciences from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $40.00 to $49.00 in a research report on Tuesday, December 5th. Finally, StockNews.com lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Tuesday, March 12th. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $45.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.